An Approach to Screening for COVID-19 at Vancouver Airport

NCT04665193 | Completed

• 1 other identifier: H20-03225
• Study Type: interventional
• Target: 592
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this pilot study is to determine the feasibility and effectiveness of a COVID-19 screening program for passengers departing from YVR. This research study is conducted by The University of British Columbia (UBC) and Providence Health Care, sponsored by WestJet and Vancouver Airport Authority. The experimental study investigates point-of-care rapid test device for detecting SARS-CoV-2, the virus responsible for COVID-19. The study is investigating a method of rapid-testing for COVID-19 and will help inform the safest and most efficient way of testing departing passengers prior to security screening at Vancouver International Airport (YVR). This study is also evaluating a new passenger management system.

Conditions

Asymptomatic Condition; Healthy

Outcome Measures

Primary Outcomes (1)

• COVID-19 status

  positive or negative screening result

  15 minutes

Study Arms (1)

Abbott Panbio test device

EXPERIMENTAL

WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device

Diagnostic Test: Rapid Antigen Test

Interventions

Rapid Antigen Test DIAGNOSTIC_TEST

Antigen Technology Lab-based test and Point of care test

Also known as: Abbott Rapid Diagnostics Panbio Covid-19 Ag Rapid Test Device (Nasopharyngeal)

Abbott Panbio test device

Eligibility Criteria

• Age: 13 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject must be between 19 and 80 years of age.
• The subject must be a resident of B.C.
• The subject must have a ticket to board a WestJet flight departing from Vancouver International Airport (YVR).
• Have a minimum of 75 minutes of free time prior to the scheduled flight's departure.
• Subject has access to accommodation in Canada for safe-isolation as per public health guidelines
• Between the ages of 13 - 90
• Travelling on any WestJet or KLM flight
• Have a minimum of 70 minutes (if travelling within Canada) or 90 minutes (if travelling International) of free time prior to the schedule flight's departure
• \-----------------------------------

You may not qualify if:

• Subjects who have previously tested positive for COVID-19 within the past 90 days
• Subjects who cannot provide written informed consent

Sponsors & Collaborators

• University of British Columbia: lead
• Vancouver Airport Authority: collaborator
• WestJet Airlines: collaborator
• Providence Health & Services: collaborator
• KLM Royal Dutch Airlines: collaborator

Study Sites (1)

Vancouver International Airport, WestJet Domestic Terminal, Level 3

Richmond, British Columbia, V7B 0A4, Canada

Location

MeSH Terms

Conditions

Asymptomatic Diseases

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Don Sin, MD

  University of British Columbia

  PRINCIPAL INVESTIGATOR

• Marc Romney, MD

  University of British Columbia

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 8, 2020
• First Posted: December 11, 2020
• Study Start: November 23, 2020
• Primary Completion: February 28, 2021
• Study Completion: April 28, 2021
• Last Updated: May 4, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)